112 citations · 264 across the 17 of their papers we have counts for
7 papers · 1 filter
CARB: A Covariate-Assessed Robust Borrowing Strategy with Literature-Informed Prior Weights for External Data
Jinping Liang, Guannan Gong, Satrajit Roychoudhury +1
Borrowing external control data can improve the efficiency of clinical trials, particularly when patient accrual is difficult. A persistent challenge is how to prespecify the degre…
Dynamic Prediction of the Target Survival Time in Metastatic Solid Tumor Cancer Clinical Trials
Sidi Wang, Kelley Kidwell, Bo Huang +1
Overall survival (OS) is the gold standard for assessing patient benefit and cost-effectiveness of new cancer drugs. However, it is often difficult to use OS as the primary endpoin…
On regional treatment effect assessment using robust MAP priors
Xin Zhang, Hui Zhang, Satrajit Roychoudhury
Bayesian dynamic borrowing has become an increasingly important tool for evaluating the consistency of regional treatment effects which is a key requirement for local regulatory ap…
Evaluating treatment effects on longitudinal outcomes with attrition due to death: Methods for a two-dimentional estimand with a case study in Quality of Life
Dries Reynders, Doranne Thomassen, Satrajit Roychoudhury +5
When longitudinal outcomes are evaluated in mortal populations, their non-existence after death complicates the analysis and its causal interpretation. Where popular methods often…
A robust score test in g-computation for covariate adjustment in randomized clinical trials leveraging different variance estimators via influence functions
Xin Zhang, Haitao Chu, Lin Liu +1
G-computation has become a widely used robust method for estimating unconditional (marginal) treatment effects with covariate adjustment in the analysis of randomized clinical tria…
Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population
Hong Zhang, Jie Pu, Shibing Deng +3
In the era of precision medicine, more and more clinical trials are now driven or guided by biomarkers, which are patient characteristics objectively measured and evaluated as indi…
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…